PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY

这是一个中期职业研究者奖在以患者为导向的研究（POR）应用程序（K24）斯图尔特R。Lessin博士将专注于皮肤肿瘤学。 Lessin博士是宾夕法尼亚大学皮肤科皮肤淋巴瘤项目的副教授和联合主任。他高度致力于POR，并在皮肤T细胞淋巴瘤（CTCL）领域拥有良好的跟踪记录（资金和出版物）。 他开发了基于T细胞受体（TCR）基因表达的淋巴增生性皮肤病分子诊断技术，并将其转化为利用TCR作为靶点的新治疗策略。 Lessin博士目前是FDA资助的I期临床试验的主要研究者，该试验测试了CTCL患者中人类TCR基因（DNA）疫苗接种的安全性和有效性。 本项目的总体研究目标是利用治疗性DNA疫苗、肽疫苗和肽模拟物技术开发和测试新的皮肤癌治疗方法。 莱辛博士一直积极参与各级POR学员的指导和培训-医学生、住院医师/研究员和初级教员。 这是通过一系列完善的POR计划实现的。目前，Lessin博士担任皮肤科皮肤肿瘤学奖学金计划，NIH培训补助金（T32），药物研究单位，Derm 800研究选修和初级教师导师计划的导师。 宾夕法尼亚大学的承诺和能力，为POR提供必要的机会和设施是非凡的。 一个完善的核心课程在POR培训，美国国立卫生研究院赞助的一般临床研究中心（GCRC）和基础和临床研究者之间的优秀互动提供了一个独特的和动态的环境中进行和培训个人在POR。 Lessin博士将参加POR核心课程和GCRC。 该奖项将为Lessin博士提供一个关键的基础设施，以追求POR并指导POR的其他研究人员。 承诺50%的努力将确保继续获得资金和保护新疗法的临床试验时间。 此外，它将使Lessin博士能够继续参与正在进行的部门和机构POR计划，并在宾夕法尼亚大学的POR中为年轻的研究人员提供榜样和导师。

This is a Midcareer Investigator Award in Patient-Oriented Research (POR) application (K24) for Stuart R. Lessin, M.D and will focus on cutaneous oncology. Dr. Lessin is Associate Professor and Co-Director of the Cutaneous Lymphoma Program in the Department of Dermatology at the University of Pennsylvania. He is highly committed to POR and has a well established track record (funding and publications) in the area of cutaneous T-cell lymphoma (CTCL). He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on T-cell receptor (TCR) gene expression and translated them into new strategies of therapy utilizing the TCR as a target. Dr. Lessin is currently the principal investigator of a FDA funded Phase I clinical trial testing the safety and efficacy of genetic (DNA) vaccination of human TCR in patients with CTCL. The overall research goal of this proposal will be to develop and test novel therapeutic approaches to skin cancers utilizing the technologies of therapeutic DNA vaccines, peptide vaccines and peptidomimetics. Dr. Lessin has been heavily involved in the mentoring and training of trainees in POR at all levels - medical students, residents/fellows and junior faculty. This has been accomplished through a series of well established POR programs. Currently, Dr. Lessin serves as a mentor in the Department of Dermatology's Cutaneous Oncology Fellowship Program, NIH Training Grant (T32), Drug Study Unit, Derm 800 Research elective and Junior Faculty Mentor's Program. The University of Pennsylvania's commitment and ability to provide opportunities and facilities necessary for POR is extraordinary. A well established Core Curriculum in POR Training, a NIH sponsored General Clinical Research Center (GCRC) and outstanding interaction between basic and clinical investigators provides a unique and dynamic environment in which to conduct and train individuals in POR. Dr. Lessin will participate in the POR core curriculum and the GCRC. This award will provide a critical infrastructure for Dr. Lessin to pursue POR and to mentor other investigators in POR. A commitment of 50 percent effort will ensure the continued acquisition of funding and protected time for clinical testing of new therapies. Furthermore, it will enable Dr. Lessin to continue to participate in the ongoing departmental and institutional POR programs and serve as a role model and mentor for young investigators in POR at the University of Pennsylvania.